Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Talha Badar

Showing results (21-30 of 113) with videos related to

Pageof 12
Sort By:
Transplantation and Cellular Therapy|June 7, 2025
Malignancies after Chimeric Antigen Receptor T Cell TherapyRazan Mohty, Amal Halwani, Talha Badar, et al.
Leukemia Research|June 7, 2025
Impact of FLT3 inhibitors on the outcomes of FLT3-ITD mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant: A systematic review and meta-analysisMuhammad Kashif Amin, Muhammad Atif Khan, Faiza Humayun Khan, et al.
Leukemia & Lymphoma|February 5, 2020
Interrogation of molecular profiles can help in differentiating between MDS and AML with MDS-related changesTalha Badar, Aniko Szabo, David Sallman, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 22, 2015
Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignanciesTalha Badar, Jorge E Cortes, Farhad Ravandi, et al.
Bone Marrow Transplantation|July 26, 2024
Assessing the efficacy of allogeneic hematopoietic cell transplantation in VEXAS syndrome: results of a systematic review and meta-analysisRazan Mohty, Tea Reljic, Nayef Abdel-Razeq, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|February 11, 2017
Detection of Novel t(12;17)(p12;p13) in Relapsed Refractory Acute Myeloid Leukemia by Anchored Multiplex PCR(AMP)-based Next-Generation SequencingTalha Badar, Laura Johnson, Katelyn Trifilo, et al.
Blood Reviews|September 7, 2023
Targeting apoptosis dysregulation in myeloid malignancies - The promise of a therapeutic revolutionEnrico Santinelli, Maria Rosaria Pascale, Zhuoer Xie, et al.
Blood Cancer Journal|November 20, 2024
What have we learned about TP53-mutated acute myeloid leukemia?Moazzam Shahzad, Muhammad Kashif Amin, Naval G Daver, et al.
Biomed Research International|February 6, 2015
Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose cytarabineTalha Badar, Jorge Cortes, Gautam Borthakur, et al.
Leukemia & Lymphoma|June 12, 2026
Real-world treatment and outcomes in hairy cell leukemia: a multicenter retrospective cohort including BRAF inhibitor therapyJames J Fradin, Lisa Rein, Aniko Szabo, et al.
Pageof 12

Showing results (21-30 of 113) with videos related to

Sort By:
Pageof 12
Transplantation and Cellular Therapy|June 7, 2025
Malignancies after Chimeric Antigen Receptor T Cell TherapyRazan Mohty, Amal Halwani, Talha Badar, et al.
Leukemia Research|June 7, 2025
Impact of FLT3 inhibitors on the outcomes of FLT3-ITD mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant: A systematic review and meta-analysisMuhammad Kashif Amin, Muhammad Atif Khan, Faiza Humayun Khan, et al.
Leukemia & Lymphoma|February 5, 2020
Interrogation of molecular profiles can help in differentiating between MDS and AML with MDS-related changesTalha Badar, Aniko Szabo, David Sallman, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 22, 2015
Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignanciesTalha Badar, Jorge E Cortes, Farhad Ravandi, et al.
Bone Marrow Transplantation|July 26, 2024
Assessing the efficacy of allogeneic hematopoietic cell transplantation in VEXAS syndrome: results of a systematic review and meta-analysisRazan Mohty, Tea Reljic, Nayef Abdel-Razeq, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|February 11, 2017
Detection of Novel t(12;17)(p12;p13) in Relapsed Refractory Acute Myeloid Leukemia by Anchored Multiplex PCR(AMP)-based Next-Generation SequencingTalha Badar, Laura Johnson, Katelyn Trifilo, et al.
Blood Reviews|September 7, 2023
Targeting apoptosis dysregulation in myeloid malignancies - The promise of a therapeutic revolutionEnrico Santinelli, Maria Rosaria Pascale, Zhuoer Xie, et al.
Blood Cancer Journal|November 20, 2024
What have we learned about TP53-mutated acute myeloid leukemia?Moazzam Shahzad, Muhammad Kashif Amin, Naval G Daver, et al.
Biomed Research International|February 6, 2015
Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose cytarabineTalha Badar, Jorge Cortes, Gautam Borthakur, et al.
Leukemia & Lymphoma|June 12, 2026
Real-world treatment and outcomes in hairy cell leukemia: a multicenter retrospective cohort including BRAF inhibitor therapyJames J Fradin, Lisa Rein, Aniko Szabo, et al.
Pageof 12